182 related articles for article (PubMed ID: 17609924)
21. Prostate cancer imaging.
Kundra V
Semin Roentgenol; 2006 Apr; 41(2):139-49. PubMed ID: 16697892
[No Abstract] [Full Text] [Related]
22. Prostate cancer metastasis to supraclavicular lymph node.
Hobdy EM; Shafi NQ; Kummar S
Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
[No Abstract] [Full Text] [Related]
23. Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH
AJR Am J Roentgenol; 2015 Sep; 205(3):W328-34. PubMed ID: 26295669
[TBL] [Abstract][Full Text] [Related]
24. [Not Available].
Bartkowiak D
Aktuelle Urol; 2016 Feb; 47(1):22-4. PubMed ID: 26903117
[No Abstract] [Full Text] [Related]
25. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
26. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.
Guo X; Han T; Hu P; Guo X; Zhu C; Wang Y; Chang S
Int Urol Nephrol; 2018 Dec; 50(12):2193-2200. PubMed ID: 30324582
[TBL] [Abstract][Full Text] [Related]
27. The current management of carcinoma of the prostate.
Rodriguez R; Carter HB
Adv Surg; 1999; 33():181-97. PubMed ID: 10572567
[No Abstract] [Full Text] [Related]
28. [Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].
Lindenmeir T; Ulrich M; Rau O; Reiher F; Allhoff EP
Urologe A; 2007 Sep; 46(9):1287. PubMed ID: 17694295
[No Abstract] [Full Text] [Related]
29. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
31. The case against extended lymph-node dissection for prostate cancer.
Huland H
Nat Clin Pract Urol; 2006 Sep; 3(9):456-7. PubMed ID: 16964181
[No Abstract] [Full Text] [Related]
32. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
33. Selective lymph node dissection for castration-resistant prostate cancer.
Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
[TBL] [Abstract][Full Text] [Related]
34. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated.
Burkhard FC; Schumacher MC; Studer UE
Nat Clin Pract Urol; 2006 Sep; 3(9):454-5. PubMed ID: 16964180
[No Abstract] [Full Text] [Related]
35. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
36. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
[TBL] [Abstract][Full Text] [Related]
37. [Cytoreductive, radical prostatectomy in metastatic prostate cancer].
Chaloupka M; Herlemann A; Spek A; Gratzke C; Stief C
Urologe A; 2017 Nov; 56(11):1430-1434. PubMed ID: 28983651
[TBL] [Abstract][Full Text] [Related]
38. Prostatic biopsy undergrading: the feasibility of secondary laparoscopic pelvic lymphadenectomy.
Hellawell G; Ramírez-Backhaus M; Rabenalt R; Do M; Dietel A; Stolzenburg JU
Urol Int; 2010; 85(2):139-42. PubMed ID: 20516675
[TBL] [Abstract][Full Text] [Related]
39. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
40. [Comment to P. J. Olbert et al., page 164].
Heidenreich A
Aktuelle Urol; 2009 May; 40(3):169-70. PubMed ID: 19479669
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
